Aesica Pharmaceuticals is doubling development capacity at its Queenborough facility, and will now be able to develop and manufacture multiple products from early formulation development through Phase III clinical manufacture and into commercialization. The company’s high potent and controlled drugs service offering has been significantly expanded. The site handles high potent drugs for any active up to SafeBridge Category 3, together with controlled drugs, with licenses for both Schedules 2 ...